169 Views

Dimension Therapeutics nets $65 mln Series B

Cambridge, Massachusetts-based Dimension Therapeutics Inc, which is focused on developing treatments for liver disorders, has closed $65 million in Series B funding. New Leaf Venture Partners led the round with participation from other investors that included Jennison Associates (on behalf of investors), Partner Fund Management, RA Capital Management, Rock Springs Capital, Tourbillon Global Ventures, Fidelity Biosciences and OrbiMed. In addition to the funding, Dr. Mike Dybbs, a partner at New Leaf Venture Partners, has been added to Dimension’s board of directors.

Edge Therapeutics racks up about $72.5 mln

Berkeley Heights, New Jersey-based Edge Therapeutics, a biotech company focused on developing therapies for neurological conditions, has secured about $72.5 million in funding from two recent rounds. The company just closed $56 million in a Series C-2 funding round led by Venrock with participation from other investors that included Sofinnova Ventures, Janus Capital Management LLC, New Leaf Venture Partners and BioMed Ventures. The earlier round, which closed in December 2014, raised $16.5 million in Series C-1 funding. The investors for that round were not named. In connection to the Series C-2 round, Dr. Anders Hove of Venrock and Dr. James Healy, a managing partner at Sofinnova Ventures, have been added to Edge Therapeutics’ board of directors.

119 Views

CardioKinetix racks up $50 mln

CardioKinetix, a Menlo Park, Calif.-based medical device firm, has received $50 million in funding. Edwards Lifesciences Corp. led the round with participation from return backers U.S. Venture Partners, Tekla Healthcare Investors, Tekla Life Sciences Investors, SV Life Sciences, Panorama Capital, New Leaf Venture Partners and Lexington Private Equity. CardioKinetix has also inked an agreement with Edwards Lifesciences Corp. that gives the latter company the option to acquire CardioKinetix “based on future regulatory milestones.”

171 Views

Truveris nets $12.75 mln Series C

Truveris said Friday that it has closed $12.75 million in Series C funding. Canaan Partners led the round with participation from return backers New Leaf Venture Partners, Tribeca Venture Partners, New Atlantic Ventures and First Round. Based in New York City, Truveris is a platform for pharmacy pricing and benefits analysis.

107 Views

QPID Health nets $12.3 mln Series B funds

QPID Health said Tuesday that it has raised $12.3 million in Series B funding. New Leaf Venture Partners led the round. In conjunction with the funding, Philippe Chambon, managing director at New Leaf Venture Partners, has been added to QPID Health’s board of directors. Headquartered in Boston, QPID Health is a provider of clinical intelligence to healthcare providers.

124 Views

Boston biotech firm Intarcia snags $200 mln

Boston-based biotech company Intarcia Therapeutics has raised $200 million financing. RA Capital led the round with participation from investors that include Farallon Capital Management, Foresite Capital, Franklin Templeton, Fred Alger Management, New Leaf Venture Partners and Quilvest.

126 Views

VC-backed Versartis raises $126 mln for IPO

Versartis has launched its IPO after pricing its 6 million shares at $21 per share. The stock began trading Friday on the NASDAQ under the ticker symbol “VSAR.” Morgan Stanley and Citigroup are the lead underwriters. Based in Redwood City, Calif., Versartis is an endocrine-focused biopharmaceutical company focused on treating growth hormone deficiency. Its backers include Sofinnova Ventures, Aisling Capital, New Leaf Venture Partners and Advent Life Sciences.

CardioKinetix Completes $48 Million Series E Round

CardioKinetix, a Menlo Park, Calif.-based medical device company, has completed the $23 million second-tranche of its Series E financing, bringing the total round to $48 million. Panorama Capital is the company’s newest investor. It joins previous investors U.S. Venture Partners, JPMorgan Partners, New Leaf Venture Partners, SV Life Sciences, H&Q Healthcare Investors, and H&Q Life Sciences Investors.

Versartis Closes Series C Financing

Versartis, an emerging biotechnology company has completed a $25 million Series C financing lead by new investor Aisling Capital. Also participating in the round were existing investors Index Ventures, New Leaf Venture Partners and Advent Venture PartnersAdvent Life Sciences fund.

Principia Biopharma Inks $12.5M

Principia Biopharma Inc., a biopharmaceutical company focused on immunology, autoimmune diseases, and oncology, has raised $12.5 million. Investors include New Leaf Venture Partners, OrbiMed Advisors, Morgenthaler Ventures, SROne and Mission Bay Capital.

Awarepoint Picks up $14M

Awarepoint Corp., the real-time location system services provider for healthcare clients, has added $14 million in funding. Heritage Group led the round and was joined by Kleiner Perkins Caufield & Byers, Cardinal Partners, Venrock, Jafco Ventures, Avalon Ventures, New Leaf Venture Partners and Top Tier Capital Partners. PRESS RELEASE: Awarepoint Raises $14 Million in Additional […]

CardioKinetix Appoints Veteran Medical Device Exec

Medical device company CardioKinetix has apointed Maria Sainz as president and chief executive officer. Recently Sainz served as general manager of Stryker Neurovascular, which acquired Concentric Medical in October 2011 under her leadership as president and CEO. CardioKinetix is backed by SV Life Sciences, New Leaf Venture Partners, U.S. Venture Partners, Panorama Capital, and H&Q […]

Truveris Inks $10M Series B

Truveris Inc. has raised $10 million in Series B financing, the company announced Thursday. New Leaf Venture Partners led the round, which also included participation from Tribeca Venture Partners, New Atlantic Ventures and First Round Capital. Formed in 2009, Truveris makes software designed to provide transparency and cost containment in the prescriptions claims process. PRESS […]

Biogen Buys VC-Backed Stromedix

Publicly traded Biogen Idec is buying venture-backed Stromedix Inc. Under the terms of the deal, Biogen Idec will make an upfront cash payment of $75 million and additional payments of up to $487.5 million based on certain milestones. Stromedix’s investors include Atlas Venture, New Leaf Venture Partners, Bessemer Venture Partners, Red Abbey Venture Partners, and […]

CardioKinetix Seals $44M For Medical Devices

CardioKinetix, a medical device company developing transcatheter implants, has raised $44 million in a two-tranche Series E financing. New investors SV Life Sciences and New Leaf Venture Partners led the round, which included return backers including U.S. Venture Partners, J.P. Morgan Partners, H&Q Healthcare Investors and H&Q Life Sciences Investors. The company’s device, dubbed Parachute, is implanted into the left ventricle of the heart in a simple catheter lab procedure and is intended to treat patients with heart failure resulting from a myocardial infarction or heart attack.

Neuronetics Nets $30M Series E

Neuronetics, the Pennsylvania-based maker of non-invasive, non-systemic treatments for depression, completed a $30 million Series E financing. New investors Polaris Venture Partners and Pfizer Venture Investments led the round and were joined by previous investors Investor Growth Capital, New Leaf Venture Partners, Interwest Partners, Three Arch Partners, Quaker BioVentures, and Onset Ventures.

PE HUB Community

Join the 12518 members of PE HUB to make connections, share your opinion, and follow your favorite authors.

Join the Community

Look Who’s Tweeting

PE HUB News Briefs

RSS Feed Widget

VCJ Headlines (subscribers only)

RSS Feed Widget

Buyouts Headlines (subscribers only)

RSS Feed Widget